The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial
Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, summarizes the findings from the Phase III IPSOS trial (NCT03191786) and the benefits of immunotherapy over chemotherapy. Despite past studies, such as the Phase III KEYNOTE-024 (NCT02142738) and KEYNOTE-042 (NCT02220894) trials recruiting performance status (PS) 1 patients, many patients with lung cancer have significant co-morbidities, and do not meet the reimbursement criteria for immunotherapy. The IPSOS trial allowed for the definition of single agent chemotherapy as being a potential treatment option. Additionally, patients were recruited with significant co-morbidities and randomised them to either atezolizumab or chemotherapy. Immunotherapy was found to provide a survival benefit that was greater than chemotherapy, with some patients undergoing chemotherapy going on to receive immunotherapy. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
